TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · no major macro event
MENS

Jyong Biotech Ltd.

Healthcare · Biotechnology

1.80$ +4.8% vs. previous close Closing price · As of: Nov 13, 2026

Ownership

Ownership Structure

Who owns Jyong Biotech Ltd. (MENS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 36.3% of the shares are freely tradable; institutional investors hold 0.7%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 0.7%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 62.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 36.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 0.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 74Mio.

Largest Shareholders

Institutions

Institutions MENS
Name Stake (%) Shares Change (%) Date
BlackRock Inc 0.35 260,317 +0.6 06/30/2026
Geode Capital Management, LLC 0.09 68,882 +7.2 06/30/2026
HRT FINANCIAL LLC 0.07 50,423 +328.5 06/30/2026
XTX Topco Ltd 0.04 29,066 +0.0 06/30/2026
Renaissance Technologies Corp 0.03 22,900 +0.0 06/30/2026
China Universal Asset Mgmt Co.Ltd 0.02 12,100 -8.1 06/30/2026

Funds

Funds MENS
Name Stake (%) Shares Change (%) Date
iShares Biotechnology ETF 0.31 226,494 -0.2 10/30/2026
iShares Nasdaq US Biotech ETF USD Acc 0.08 60,018 +0.2 10/30/2026
Fidelity Nasdaq Composite Index 0.06 46,713 +0.0 08/31/2026
Fidelity Nasdaq Composite ETF 0.04 26,899 +0.0 10/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?